Your browser doesn't support javascript.
loading
Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma.
Lukovic, J; Alfaraj, F A; Mierzwa, M L; Marta, G N; Xu, W; Su, J; Moraes, F Y; Huang, S H; Bratman, S V; O'Sullivan, B; Kim, J J; Ringash, J G; Waldron, J; de Almeida, J R; Goldstein, D P; Casper, K A; Rosko, A J; Spector, M E; Kowalski, L P; Hope, A; Hosni, A.
Afiliação
  • Lukovic J; Department of Radiation Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
  • Alfaraj FA; Department of Radiation Oncology, BC Cancer Agency Centre for the North, Prince George, Canada.
  • Mierzwa ML; Department of Radiation Oncology, University of Michigan, Ann Arbor, USA.
  • Marta GN; Department of Radiation Oncology, Hospital Sírio-Libanês, Sao Paulo, Brazil.
  • Xu W; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada.
  • Su J; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada.
  • Moraes FY; Department of Radiation Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
  • Huang SH; Department of Radiation Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
  • Bratman SV; Department of Radiation Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
  • O'Sullivan B; Department of Radiation Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
  • Kim JJ; Department of Radiation Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
  • Ringash JG; Department of Radiation Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
  • Waldron J; Department of Radiation Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
  • de Almeida JR; Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
  • Goldstein DP; Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
  • Casper KA; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, USA.
  • Rosko AJ; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, USA.
  • Spector ME; Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, USA.
  • Kowalski LP; Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center, Sao Paulo, Brazil.
  • Hope A; Department of Radiation Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
  • Hosni A; Department of Radiation Oncology, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada. Electronic address: ali.hosni@rmp.uhn.ca.
Ann Oncol ; 31(2): 295-301, 2020 02.
Article em En | MEDLINE | ID: mdl-31959347
ABSTRACT

BACKGROUND:

The most common pattern of failure in major salivary gland carcinoma (SGC) is development of distant metastases (DMs). The objective of this study was to develop and validate a prediction score for DM in SGC. PATIENTS AND

METHODS:

Patients with SGC treated curatively at four tertiary cancer centers were divided into discovery (n = 619) and validation cohorts (n = 416). Multivariable analysis using competing risk regression was used to identify predictors of DM in the discovery cohort and create a prediction score of DM; the optimal score cut-off was determined using a minimal P value approach. The prediction score was subsequently evaluated in the validation cohort. The cumulative incidence and Kaplan-Meier methods were used to analyze DM and overall survival (OS), respectively.

RESULTS:

In the discovery cohort, DM predictors (risk coefficient) were positive margin (0.6), pT3-4 (0.7), pN+ (0.7), lymphovascular invasion (0.8), and high-risk histology (1.2). High DM-risk SGC was defined by sum of coefficients greater than two. In the discovery cohort, the 5-year incidence of DM for high- versus low-risk SGC was 50% versus 8% (P < 0.01); this was similar in the validation cohort (44% versus 4%; P < 0.01). In the pooled cohorts, this model performed similarly in predicting distant-only failure (40% versus 6%, P < 0.01) and late (>2 years post surgery) DM (22% versus 4%; P < 0.01). Patients with high-risk SGC had an increased incidence of DM in the subgroup receiving postoperative radiation therapy (46% versus 8%; P < 0.01). The 5-year OS for high- versus low-risk SGC was 48% versus 92% (P < 0.01).

CONCLUSION:

This validated prediction-score model may be used to identify SGC patients at increased risk for DM and select those who may benefit from prospective evaluation of treatment intensification and/or surveillance strategies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias das Glândulas Salivares / Carcinoma Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias das Glândulas Salivares / Carcinoma Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article